BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28704852)

  • 1. Pregnancy and Tumor Outcomes in Women with Prolactinoma.
    Araujo B; Belo S; Carvalho D
    Exp Clin Endocrinol Diabetes; 2017 Nov; 125(10):642-648. PubMed ID: 28704852
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prolactinoma and pregnancy].
    Trifonov I
    Akush Ginekol (Sofiia); 2004; 43 Suppl 2():16-22. PubMed ID: 15518268
    [No Abstract]   [Full Text] [Related]  

  • 3. Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.
    Lebbe M; Hubinont C; Bernard P; Maiter D
    Clin Endocrinol (Oxf); 2010 Aug; 73(2):236-42. PubMed ID: 20455894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy.
    Rastogi A; Bhadada SK; Bhansali A
    Gynecol Endocrinol; 2017 Apr; 33(4):270-273. PubMed ID: 27908214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation.
    Auriemma RS; Perone Y; Di Sarno A; Grasso LF; Guerra E; Gasperi M; Pivonello R; Colao A
    J Clin Endocrinol Metab; 2013 Jan; 98(1):372-9. PubMed ID: 23162092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactinoma and pregnancy: From the wish of conception to lactation.
    Maiter D
    Ann Endocrinol (Paris); 2016 Jun; 77(2):128-34. PubMed ID: 27130071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
    Yarman S; Kurtulmus N; Bilge A
    Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An observational study of pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists.
    O'Sullivan SM; Farrant MT; Ogilvie CM; Gunn AJ; Milsom SR
    Aust N Z J Obstet Gynaecol; 2020 Jun; 60(3):405-411. PubMed ID: 31583693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactin-secreting tumors, dopamine agonists and pregnancy: a longitudinal experience of a tertiary neuroendocrine center.
    Prencipe N; Bona C; Cuboni D; Berton AM; Bioletto F; Varaldo E; Aversa LS; Sibilla M; Gasco V; Ghigo E; Grottoli S
    Pituitary; 2024 Jun; 27(3):269-276. PubMed ID: 38499816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolactinoma and pregnancy - a series of cases including pituitary apoplexy.
    Galvão A; Gonçalves D; Moreira M; Inocêncio G; Silva C; Braga J
    J Obstet Gynaecol; 2017 Apr; 37(3):284-287. PubMed ID: 27866462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of prolactinomas during pregnancy.
    Witek P; Zieliński G
    Minerva Endocrinol; 2013 Dec; 38(4):351-63. PubMed ID: 24285103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical practice. Prolactinomas.
    Klibanski A
    N Engl J Med; 2010 Apr; 362(13):1219-26. PubMed ID: 20357284
    [No Abstract]   [Full Text] [Related]  

  • 15. Dopamine receptor agonists for treating prolactinomas.
    Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
    Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation.
    Rains CP; Bryson HM; Fitton A
    Drugs; 1995 Feb; 49(2):255-79. PubMed ID: 7729332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabergoline treatment of pregnant women with macroprolactinomas.
    Laloi-Michelin M; Ciraru-Vigneron N; Meas T
    Int J Gynaecol Obstet; 2007 Oct; 99(1):61-2. PubMed ID: 17602689
    [No Abstract]   [Full Text] [Related]  

  • 18. Prolactinoma in pregnancy.
    Molitch ME
    Best Pract Res Clin Endocrinol Metab; 2011 Dec; 25(6):885-96. PubMed ID: 22115164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
    Hu J; Zheng X; Zhang W; Yang H
    Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose cabergoline therapy for a resistant macroprolactinoma during pregnancy.
    Banerjee A; Wynne K; Tan T; Hatfield EC; Martin NM; Williamson C; Meeran K
    Clin Endocrinol (Oxf); 2009 May; 70(5):812-3. PubMed ID: 18803677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.